Skip to main content

Advertisement

SpringerLink
Log in

Insulin resistance and PCOS: chicken or egg?

  • Review
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

PCOS is a common and heterogeneous endocrine disorder in women of reproductive age, frequently associated with metabolic abnormalities. It was estimated that about 75% of these subjects have an impairment of insulin action, as measured by gold standard methods. While the relationship between insulin resistance and PCOS is consistently shown by a number of studies, the mechanisms underlying its primary origin still remains an unsolved issue. Insulin resistance and the associated hyperinsulinemia can induce both the endocrine and reproductive traits of PCOS. However, androgen excess, in turn, can impair insulin action, directly and/or through several changes occurring in different tissues. Body fat excess, which is another common feature in these women, can contribute to worsening the whole picture. Nevertheless, insulin resistance may also be found in many normal-weight individuals. Endocrine and metabolic abnormalities can develop in different moments, and probably there is fetal programming of these alterations. However, a number of vicious circles, with bidirectional relationships between androgen excess and insulin resistance, and with the contribution of several other factors, make it extremely difficult to understand where this process really originates. This review summarizes available evidence on this topic, in order to better understand the complex relationships linking hyperandrogenism and impaired insulin action in women with PCOS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Reproduced with permission from Moghetti et al. [5]

Fig. 2
Fig. 3

Reproduced with permission from Tosi et al. [22]

Fig. 4

Reproduced with permission from Tosi et al. [33]

Similar content being viewed by others

References

  1. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome (PCOS). The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Hum Reprod 19:41–47

    Google Scholar 

  2. Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R (2016) Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril 106:6–15

    PubMed  Google Scholar 

  3. World Health Organization (1999) Definition, Diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. World Health Organization, Geneva

    Google Scholar 

  4. Tosi F, Bonora E, Moghetti P (2017) Insulin resistance in a large cohort of women with polycystic ovary syndrome: a comparison between euglycaemic-hyperinsulinaemic clamp and surrogate indexes. Hum Reprod 32:2515–2521

    CAS  PubMed  Google Scholar 

  5. Moghetti P, Tosi F, Bonin C, Di Sarra D, Fiers T, Kaufman JM, Giagulli VA, Signori C, Zambotti F, Dall'Alda M, Spiazzi G, Zanolin ME, Bonora E (2013) Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. J Clin Endocrinol Metab 98:E628–637

    CAS  PubMed  Google Scholar 

  6. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE (2005) Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90:1929–1935

    CAS  PubMed  Google Scholar 

  7. Cassar S, Misso ML, Hopkins WG, Shaw CS, Teede HJ, Stepto NK (2016) Insulin resistance in polycystic ovary syndrome: a systematic review and metaanalysis of euglycaemic hyperinsulinaemic clamp studies. Hum Reprod 31:2619–2631

    CAS  PubMed  Google Scholar 

  8. Dunaif A, Xia J, Book CB, Schenker E, Tang Z (1995) Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Investig 96:801–810

    CAS  PubMed  Google Scholar 

  9. Corbould A, Zhao H, Mirzoeva S, Aird F, Dunaif A (2006) Enhanced mitogenic signalling in skeletal muscle of women with polycystic ovary syndrome. Diabetes 55:751–759

    CAS  PubMed  Google Scholar 

  10. Diamanti-Kandarakis E, Dunaif A (2012) Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 33:981–1030

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Ciaraldi TP (2000) Molecular defects of insulin action in the polycystic ovary syndrome: possible tissue specificity. J Pediatr Endocrinol Metab 13(Suppl 5):1291–1293

    PubMed  Google Scholar 

  12. Højlund K, Glintborg D, Andersen NR, Birk JB, Treebak JT, Frøsig C, Beck-Nielsen H, Wojtaszewski JF (2008) Impaired insulin-stimulated phosphorylation of Akt and AS160 in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment. Diabetes 57:357–366

    PubMed  Google Scholar 

  13. Hansen SL, Svendsen PF, Jeppesen JF, Hoeg LD, Andersen NR, Kristensen JM, Nilas L, Lundsgaard AM, Wojtaszewski JFP, Madsbad S, Kiens B (2019) Molecular mechanisms in skeletal muscle underlying insulin resistance in women who are lean with polycystic ovary syndrome. J Clin Endocrinol Metab 104:1841–1854

    PubMed  Google Scholar 

  14. Nelson-Degrave VL, Wickenheisser JK, Hendricks KL, Asano T, Fujishiro M, Legro RS, Kimball SR, Strauss JF 3rd, McAllister JM (2005) Alterations in mitogen-activated protein kinase kinase and extracellular regulated kinase signaling in theca cells contribute to excessive androgen production in polycystic ovary syndrome. Mol Endocrinol 19:379–390

    CAS  PubMed  Google Scholar 

  15. Dumesic DA, Hoyos LR, Chazenbalk GD, Naik R, Padmanabhan V, Abbott DH (2020) Mechanisms of intergenerational transmission of polycystic ovary syndrome. Reproduction 159:R1–R13

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Johnson T, Kaplan L, Ouyang P, Rizza P (2012) National Institutes of Health evidence-based methodology workshop on polycystic ovary syndrome. NIH EbMW reports. National Institutes of Health, Bethesda 1:1–14. https://www.prevention.nih.gov/sites/default/files/2018-06/FinalReport.pdf. Accessed 31 Mar 2020

  17. Holte J, Bergh T, Berne C, Berglund L, Lithell H (1994) Enhanced early insulin response to glucose in relation to insulin resistance in women with polycystic ovary syndrome and normal glucose tolerance. J Clin Endocrinol Metab 78:1052–1058

    CAS  PubMed  Google Scholar 

  18. Stepto NK, Cassar S, Joham AE, Hutchison SK, Harrison CL, Goldstein RF, Teede HJ (2013) Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic–hyperinsulinaemic clamp. Hum Reprod 28:777–784

    CAS  PubMed  Google Scholar 

  19. Carmina E, Bucchieri S, Esposito A, Del Puente A, Mansueto P, Orio F, Di Fede G, Rini G (2007) Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J Clin Endocrinol Metab 92:2500–2505

    CAS  PubMed  Google Scholar 

  20. Dumesic DA, Akopians AL, Madrigal VK, Ramirez E, Margolis DJ, Sarma MK, Thomas AM, Grogan TR, Haykal R, Schooler TA, Okeya BL, Abbott DH, Chazenbalk GD (2016) Hyperandrogenism accompanies increased intra-abdominal fat storage in normal weight polycystic ovary syndrome women. J Clin Endocrinol Metab 101:4178–4188

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Mannerås-Holm L, Leonhardt H, Kullberg J, Jennische E, Odén A, Holm G, Hellström M, Lönn L, Olivecrona G, Stener-Victorin E, Lönn M (2011) Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab 96:E304–311

    PubMed  Google Scholar 

  22. Tosi F, Di Sarra D, Kaufman JM, Bonin C, Moretta R, Bonora E, Zanolin E, Moghetti P (2015) Total body fat and central fat mass independently predict insulin resistance but not hyperandrogenemia in women with polycystic ovary syndrome. J Clin Endocrinol Metab 100:661–669

    CAS  PubMed  Google Scholar 

  23. Barber TM, Hanson P, Weickert MO, Franks S (2019) Obesity and polycystic ovary syndrome: implications for pathogenesis and novel management strategies. Clin Med Insights Reprod Health 13:1179558119874042

    PubMed  PubMed Central  Google Scholar 

  24. Lizneva D, Kirubakaran R, Mykhalchenko K, Suturina L, Chernukha G, Diamond MP, Azziz R (2016) Phenotypes and body mass in women with polycystic ovary syndrome identified in referral versus unselected populations: systematic review and meta-analysis. Fertil Steril 106:1510–1520.e2

    PubMed  Google Scholar 

  25. Brower MA, Hai Y, Jones MR, Guo X, Chen Y-DI, Rotter JI, Krauss RM, Legro RS, Azziz R, Goodarzi MO (2019) Bidirectional Mendelian randomization to explore the causal relationships between body mass index and polycystic ovary syndrome. Hum Reprod 34:127–136

    CAS  PubMed  Google Scholar 

  26. Zhao Y, Xu Y, Wang X, Xu L, Chen J, Gao C et al (2020) Body mass index and polycystic ovary syndrome: a 2-sample bidirectional Mendelian randomization study. J Clin Endocrinol Metab 105:dgaa25

    Google Scholar 

  27. Joo YY, Actkins K, Pacheco JA, Basile AO, Carroll R, Crosslin DR et al (2020) A polygenic and phenotypic risk prediction for polycystic ovary syndrome evaluated by phenome-wide association studies. J Clin Endocrinol Metab 105:dgz326

    PubMed  Google Scholar 

  28. Moran LJ, Misso ML, Wild RA, Norman RJ (2010) Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 16:347–363

    CAS  PubMed  Google Scholar 

  29. Gambineri A, Patton L, Altieri P, Pagotto U, Pizzi C, Manzoli L, Pasquali R (2012) Polycystic ovary syndrome is a risk factor for type 2 diabetes: results from a long-term prospective study. Diabetes 61:2369–2374

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Glintborg D, Hass Rubin K, Nybo M, Abrahamsen B, Andersen M (2015) Morbidity and medicine prescriptions in a nationwide Danish population of patients diagnosed with polycystic ovary syndrome. Eur J Endocrinol 172:627–638

    CAS  PubMed  Google Scholar 

  31. Kakoly NS, Earnest A, Teede HJ, Moran LJ, Joham AE (2019) The impact of obesity on the incidence of type 2 diabetes among women with polycystic ovary syndrome. Diabetes Care 42:560–567

    PubMed  Google Scholar 

  32. Conn JJ, Jacobs HS, Conway GS (2000) The prevalence of polycystic ovaries in women with type 2 diabetes mellitus. Clin Endocrinol (Oxf) 52:81–86

    CAS  Google Scholar 

  33. Peppard HR, Marfori J, Iuorno MJ, Nestler JE (2001) Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes. Diabetes Care 24:1050–1052

    CAS  PubMed  Google Scholar 

  34. Zargar AH, Gupta VK, Wani AI, Masoodi SR, Bashir MI, Laway BA, Ganie MA, Salahuddin M (2005) Prevalence of ultrasonography proved polycystic ovaries in North Indian women with type 2 diabetes mellitus. Reprod Biol Endocrinol 3:35

    PubMed  PubMed Central  Google Scholar 

  35. Kelestimur F, Unluhizarci K, Baybuga H, Atmaca H, Bayram F, Sahin Y (2006) Prevalence of polycystic ovarian changes and polycystic ovary syndrome in premenopausal women with treated type 2 diabetes mellitus. Fertil Steril 86:405–410

    PubMed  Google Scholar 

  36. Marchetti P, Bugliani M, Boggi U, Masini M, Marselli L (2012) The pancreatic beta cells in human type 2 diabetes. Adv Exp Med Biol 771:288–309

    PubMed  Google Scholar 

  37. Pasquali R, Gambineri A (2018) New perspectives on the definition and management of polycystic ovary syndrome. J Endocrinol Investig 41:1123–1135

    CAS  Google Scholar 

  38. Tosi F, Fiers T, Kaufman JM, Dall'Alda M, Moretta R, Giagulli VA, Bonora E, Moghetti P (2016) Implications of androgen assay accuracy in the phenotyping of women with polycystic ovary syndrome. J Clin Endocrinol Metab 101:610–618

    CAS  PubMed  Google Scholar 

  39. Mooradian AD, Morley JE, Korenman SG (1987) Biological actions of androgens. Endocr Rev 8:1–28

    CAS  PubMed  Google Scholar 

  40. O'Reilly MW, Kempegowda P, Jenkinson C, Taylor AE, Quanson JL, Storbeck KH, Arlt W (2017) 11-Oxygenated C19 steroids are the predominant androgens in polycystic ovary syndrome. J Clin Endocrinol Metab 102:840–848

    PubMed  Google Scholar 

  41. Rege J, Turcu AF, Kasa-Vubu JZ, Lerario AM, Auchus GC, Auchus RJ, Smith JM, White PC, Rainey WE (2018) 11-Ketotestosterone is the dominant circulating bioactive androgen during normal and premature adrenarche. J Clin Endocrinol Metab 103:4589–4598

    PubMed  PubMed Central  Google Scholar 

  42. Turcu AF, Nanba AT, Chomic R, Upadhyay SK, Giordano TJ, Shields JJ, Merke DP, Rainey WE, Auchus RJ (2016) Adrenal-derived 11-oxygenated 19-carbon steroids are the dominant androgens in classic 21-hydroxylase deficiency. Eur J Endocrinol 174:601–609

    PubMed  PubMed Central  Google Scholar 

  43. Dahan MH, Abbasi F, Reaven G (2019) Relationship between surrogate estimates and direct measurement of insulin resistance in women with polycystic ovary syndrome. J Endocrinol Investig 42:987–993

    CAS  Google Scholar 

  44. Duckworth WC, Bennett RG, Hamel FG (1998) Insulin degradation: progress and potential. Endocr Rev 19:608–624

    CAS  PubMed  Google Scholar 

  45. Buffington CK, Kitabchi AE (1994) Evidence for a defect in insulin metabolism in hyperandrogenic women with polycystic ovarian syndrome. Metabolism 43:1367–1372

    CAS  PubMed  Google Scholar 

  46. Tosi F, Dal Molin F, Zamboni F, Saggiorato E, Salvagno GL, Fiers T, Kaufman JM, Bonora E, Moghetti P (2020) Serum androgens are independent predictors of insulin clearance but not of insulin secretion in women with PCOS. J Clin Endocrinol Metab 105:dgaa095 (E-pub ahead of print)

    PubMed  Google Scholar 

  47. Legro RS, Driscoll D, Strauss JF 3rd, Fox J, Dunaif A (1998) Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci USA 95:14956–14960

    CAS  PubMed  Google Scholar 

  48. Sam S, Legro RS, Essah PA, Apridonidze T, Dunaif A (2006) Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome. Proc Natl Acad Sci USA 103:7030–7035

    CAS  PubMed  Google Scholar 

  49. Sir-Petermann T, Codner E, Pérez V, Echiburú B, Maliqueo M, Ladrón de Guevara A, Preisler J, Crisosto N, Sánchez F, Cassorla F, Bhasin S (2009) Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 94:1923–1930

    CAS  PubMed  PubMed Central  Google Scholar 

  50. Yilmaz B, Vellanki P, Ata B, Yildiz BO (2018) Diabetes mellitus and insulin resistance in mothers, fathers, sisters, and brothers of women with polycystic ovary syndrome: a systematic review and meta-analysis. Fertil Steril 110:523–533

    PubMed  Google Scholar 

  51. Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI (2006) Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab 91:2100–2104

    CAS  PubMed  Google Scholar 

  52. Hiam D, Moreno-Asso A, Teede HJ, Laven JSE, Stepto NK, Moran LJ, Gibson-Helm M (2019) The genetics of polycystic ovary syndrome: an overview of candidate gene systematic reviews and genome-wide association studies. J Clin Med 8(10):1606

    CAS  PubMed Central  Google Scholar 

  53. Day F, Karaderi T, Jones MR et al (2018) Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria. PLoS Genet 14:e1007813

    PubMed  PubMed Central  Google Scholar 

  54. Cannarella R, Condorelli RA, Mongioì LM, La Vignera S, Calogero AE (2018) Does a male polycystic ovarian syndrome equivalent exist? J Endocrinol Investig 41:49–57

    CAS  Google Scholar 

  55. Chen B, Xu P, Wang J, Zhang C (2019) The role of MiRNA in polycystic ovary syndrome (PCOS). Gene 706:91–96

    CAS  PubMed  Google Scholar 

  56. Nilsson E, Benrick A, Kokosar M, Krook A, Lindgren E, Källman T, Martis MM, Højlund K, Ling C, Stener-Victorin E (2018) Transcriptional and epigenetic changes influencing skeletal muscle metabolism in women with polycystic ovary syndrome. J Clin Endocrinol Metab 103:4465–4477

    PubMed  Google Scholar 

  57. Murri M, Insenser M, Fernández-Durán E, San-Millán JL, Luque-Ramírez M, Escobar-Morreale HF (2018) Non-targeted profiling of circulating microRNAs in women with polycystic ovary syndrome (PCOS): effects of obesity and sex hormones. Metabolism 86:49–60

    CAS  PubMed  Google Scholar 

  58. Che Q, Liu M, Zhang D, Lu Y, Xu J, Lu X, Cao X, Liu Y, Dong X, Liu S (2020) Long noncoding RNA HUPCOS promotes follicular fluid androgen excess in PCOS patients via aromatase inhibition. J Clin Endocrinol Metab 105:dgaa060

    PubMed  Google Scholar 

  59. Vilariño-García T, Pérez-Pérez A, Santamaría-López E, Prados N, Fernández-Sánchez M, Sánchez-Margalet V (2020) Sam68 mediates leptin signaling and action in human granulosa cells: possible role in leptin resistance in PCOS. Endocr Connect 9:479–488

    PubMed  PubMed Central  Google Scholar 

  60. Che Q, Liu M, Xu J, Liu Y, Cao X, Dong X, Liu S (2019) Characterization of circular RNA expression profiles in cumulus cells from patients withpolycystic ovary syndrome. Fertil Steril 111:1243–1251.e1

    CAS  PubMed  Google Scholar 

  61. Vázquez-Martínez ER, Gómez-Viais YI, García-Gómez E, Reyes-Mayoral C, Reyes-Muñoz E, Camacho-Arroyo I, Cerbón M (2019) DNA methylation in the pathogenesis of polycystic ovary syndrome. Reproduction 158:R27–R40

    PubMed  Google Scholar 

  62. Wang XX, Wei JZ, Jiao J, Jiang SY, Yu DH, Li D (2014) Genome-wide DNA methylation and gene expression patterns provide insight into polycystic ovary syndrome development. Oncotarget 5:6603–6610

    PubMed  PubMed Central  Google Scholar 

  63. Lambertini L, Saul SR, Copperman AB, Hammerstad SS, Yi Z, Zhang W, Tomer Y, Kase N (2017) Intrauterine reprogramming of the polycystic ovary syndrome: evidence from a pilot study of cord blood global methylation analysis. Front Endocrinol (Lausanne) 8:352

    Google Scholar 

  64. Echiburú B, Milagro F, Crisosto N, Pérez-Bravo F, Flores C, Arpón A, Salas-Pérez F, Recabarren SE, Sir-Petermann T, Maliqueo M (2020) DNA methylation in promoter regions of genes involved in the reproductive and metabolic function of children born to women with PCOS. Epigenetics. https://doi.org/10.1080/15592294.2020.1754674

    Article  PubMed  Google Scholar 

  65. Abbott DH, Dumesic DA, Levine JE (2019) Hyperandrogenic origins of polycystic ovary syndrome—implications for pathophysiology and therapy. Expert Rev Endocrinol Metab 14:131–143

    CAS  PubMed  PubMed Central  Google Scholar 

  66. Walters KA, Gilchrist RB, Ledger WL, Teede HJ, Handelsman DJ, Campbell RE (2018) New perspectives on the pathogenesis of PCOS: neuroendocrine origins. Trends Endocrinol Metab 29:841–852

    CAS  PubMed  Google Scholar 

  67. Morford JJ, Wu S, Mauvais-Jarvis F (2018) The impact of androgen actions in neurons on metabolic health and disease. Mol Cell Endocrinol 465:92–102

    CAS  PubMed  Google Scholar 

  68. Navarro G, Allard C, Morford JJ et al (2018) Androgen excess in pancreatic β cells and neurons predisposes female mice to type 2 diabetes. JCI Insight 3(12):e98607

    PubMed Central  Google Scholar 

  69. Sir-Petermann T, Maliqueo M, Angel B, Lara HE, Pérez-Bravo F, Recabarren SE (2002) Maternal serum androgens in pregnant women with polycystic ovarian syndrome: possible implications in prenatal androgenization. Hum Reprod 17:2573–2579

    CAS  PubMed  Google Scholar 

  70. Tata B, Mimouni NEH, Barbotin AL et al (2018) Elevated prenatal anti-Müllerian hormone reprograms the fetus and induces polycystic ovary syndrome in adulthood. Nat Med 24:834–846

    CAS  PubMed  PubMed Central  Google Scholar 

  71. Dulka EA, Moenter SM (2017) Prepubertal development of gonadotropin-releasing hormone neuron activity is altered by sex, age, and prenatal androgen exposure. Endocrinology 158:3943–3953

    CAS  PubMed  PubMed Central  Google Scholar 

  72. Cardoso RC, Burns A, Moeller J, Skinner DC, Padmanabhan V (2016) Developmental programming: insulin sensitizer prevents the GnRH-stimulated LH hypersecretion in a sheep model of PCOS. Endocrinology 157:4641–4653

    CAS  PubMed  PubMed Central  Google Scholar 

  73. Bar RS, Muggeo M, Roth J (1979) Insulin resistant syndromes in humans. Adv Exp Med Biol 124:85–104

    CAS  PubMed  Google Scholar 

  74. Malek R, Chong AY, Lupsa BC, Lungu AO, Cochran EK, Soos MA, Semple RK, Balow JE, Gorden P (2010) Treatment of type B insulin resistance: a novel approach to reduce insulin receptor autoantibodies. J Clin Endocrinol Metab 95:3641–3647

    CAS  PubMed  PubMed Central  Google Scholar 

  75. Wu S, Divall S, Nwaopara A, Radovick S, Wondisford F, Ko C, Wolfe A (2014) Obesity-induced infertility and hyperandrogenism are corrected by deletion of the insulin receptor in the ovarian theca cell. Diabetes 63:1270–1282

    CAS  PubMed  PubMed Central  Google Scholar 

  76. Nestler JE, Jakubowicz DJ, de Vargas AF, Brik C, Quintero N, Medina F (1998) Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 83:2001–2005

    CAS  PubMed  Google Scholar 

  77. Tosi F, Negri C, Perrone F, Dorizzi R, Castello R, Bonora E, Moghetti P (2012) Hyperinsulinemia amplifies GnRH agonist stimulated ovarian steroid secretion in women with polycystic ovary syndrome. J Clin Endocrinol Metab 97:1712–1719

    CAS  PubMed  Google Scholar 

  78. Moghetti P, Castello R, Negri C, Tosi F, Spiazzi GG, Brun E, Balducci R, Toscano V, Muggeo M (1996) Insulin infusion amplifies 17 alpha-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent relative impairment of 17,20-lyase activity. J Clin Endocrinol Metab 81:881–886

    CAS  PubMed  Google Scholar 

  79. Tosi F, Negri C, Brun E, Castello R, Faccini G, Bonora E, Muggeo M, Toscano V, Moghetti P (2011) Insulin enhances ACTH-stimulated androgen and glucocorticoid metabolism in hyperandrogenic women. Eur J Endocrinol 164:197–203

    CAS  PubMed  Google Scholar 

  80. Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH (2017) Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, d-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev 11:CD003053

    PubMed  Google Scholar 

  81. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E, Muggeo M (2000) Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 85:139–146

    CAS  PubMed  Google Scholar 

  82. Polderman KH, Gooren LJ, Asscheman H, Bakker A, Heine RJ (1994) Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metab 79:265–271

    CAS  PubMed  Google Scholar 

  83. Diamond MP, Grainger D, Diamond MC, Sherwin RS, Defronzo RA (1998) Effects of methyltestosterone on insulin secretion and sensitivity in women. J Clin Endocrinol Metab 83:4420–4425

    CAS  PubMed  Google Scholar 

  84. Moghetti P, Tosi F, Castello R, Magnani CM, Negri C, Brun E, Furlani L, Caputo M, Muggeo M (1996) The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. J Clin Endocrinol Metab 81:952–960

    CAS  PubMed  Google Scholar 

  85. Holmäng A, Svedberg J, Jennische E, Björntorp P (1990) Effects of testosterone on muscle insulin sensitivity and morphology in female rats. Am J Physiol 259:E555–560

    PubMed  Google Scholar 

  86. Bacchi E, Negri C, Di Sarra D, Tosi F, Tarperi C, Moretta R, Schena F, Bonora E, Kaufman JM, Moghetti P (2015) Serum testosterone predicts cardiorespiratory fitness impairment in normal-weight women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 83:895–901

    CAS  Google Scholar 

  87. Corbould A (2007) Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women. J Endocrinol 192:585–594

    CAS  PubMed  Google Scholar 

  88. O'Reilly MW, Kempegowda P, Walsh M, Taylor AE, Manolopoulos KN, Allwood JW, Semple RK, Hebenstreit D, Dunn WB, Tomlinson JW, Arlt W (2017) AKR1C3-mediated adipose androgen generation drives lipotoxicity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 102:3327–3339

    PubMed  PubMed Central  Google Scholar 

  89. Ek I, Arner P, Rydén M, Holm C, Thörne A, Hoffstedt J, Wahrenberg H (2002) A unique defect in the regulation of visceral fat cell lipolysis in the polycystic ovary syndrome as an early link to insulin resistance. Diabetes 51:484–492

    CAS  PubMed  Google Scholar 

  90. González F, Nair KS, Daniels JK, Basal E, Schimke JM (2012) Hyperandrogenism sensitizes mononuclear cells to promote glucose-induced inflammation in lean reproductive-age women. Am J Physiol Endocrinol Metab 302:E297–306

    PubMed  Google Scholar 

  91. Di Sarra D, Tosi F, Bonin C, Fiers T, Kaufman JM, Signori C, Zambotti F, Dall'Alda M, Caruso B, Zanolin ME, Bonora E, Moghetti P (2013) Metabolic inflexibility is a feature of women with polycystic ovary syndrome and is associated with both insulin resistance and hyperandrogenism. J Clin Endocrinol Metab 98:2581–2588

    PubMed  Google Scholar 

  92. Ruth KS, Day FR, Tyrrell J et al (2020) Using human genetics to understand the disease impacts of testosterone in men and women. Nat Med 26:252–258

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This work was supported by academic grants to Paolo Moghetti from the University of Verona.

Author information

Authors and Affiliations

  1. Unit of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Verona and Azienda Ospedaliera Universitaria Integrata Verona, P.le Stefani, 1, 37126, Verona, Italy

    P. Moghetti & F. Tosi

Authors
  1. P. Moghetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Tosi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Moghetti.

Ethics declarations

Conflict of interest

The authors have nothing to disclose.

Ethical approval

Ethical approval was not required for this review article.

Informed consent

Informed consent was not required for this review article.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moghetti, P., Tosi, F. Insulin resistance and PCOS: chicken or egg?. J Endocrinol Invest 44, 233–244 (2021). https://doi.org/10.1007/s40618-020-01351-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40618-020-01351-0

Keywords

Search

Navigation